{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:15Z","timestamp":1788964935075,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-025-00254-7","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:03:00Z","timestamp":1752530580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Challenges in subtyping disease entities of thyroid dysfunction following combined immune checkpoint inhibitor therapy: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Marco Juul","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6336-1936","authenticated-orcid":false,"given":"Stine Linding","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna Maria Uldall","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Carl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"254_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187:G1\u201321.","journal-title":"Eur J Endocrinol"},{"key":"254_CR2","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","volume":"21","author":"R Hattersley","year":"2021","unstructured":"Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021;21:e212\u201322.","journal-title":"Clin Med (Lond)"},{"key":"254_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.humimm.2017.12.013","volume":"79","author":"K Kawai","year":"2018","unstructured":"Kawai K, Uchiyama M, Hester J, Wood K, Issa F. Regulatory T cells for tolerance. Hum Immunol. 2018;79:294\u2013303.","journal-title":"Hum Immunol"},{"key":"254_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-med-050219-034237","volume":"72","author":"Z Quandt","year":"2021","unstructured":"Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS. Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors. Annu Rev Med. 2021;72:313\u201330.","journal-title":"Annu Rev Med"},{"key":"254_CR5","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.3390\/jcm12155161","volume":"12","author":"NI Profili","year":"2023","unstructured":"Profili NI, Castelli R, Gidaro A, Merella A, Manetti R, Palmieri G, et al. Endocrine side effects in patients treated with immune checkpoint inhibitors: A narrative review. J Clin Med. 2023;12:5161.","journal-title":"J Clin Med"},{"key":"254_CR6","doi-asserted-by":"publisher","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","volume":"13","author":"A Chera","year":"2022","unstructured":"Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2022;13:1010279.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"254_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint Blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"254_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","volume":"85","author":"D Karaviti","year":"2024","unstructured":"Karaviti D, Kani ER, Karaviti E, Gerontiti E, Michalopoulou O, Stefanaki K, et al. Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 2024;85:67\u201379.","journal-title":"Endocrine"},{"key":"254_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00520-024-08445-y","volume":"32","author":"SK Christensen","year":"2024","unstructured":"Christensen SK, Winther ML, Laursen IJ, Madsen FS, Brink C, Brix TH, et al. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III\/IV melanoma treated with adjuvant PD-1 inhibitors: a National cohort study. Support Care Cancer. 2024;32:281.","journal-title":"Support Care Cancer"},{"key":"254_CR10","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/cancers13081944","volume":"13","author":"M Peiffert","year":"2021","unstructured":"Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E, et al. Graves\u2019 disease during immune checkpoint inhibitor therapy (A case series and literature Review). Cancers (Basel). 2021;13:1944.","journal-title":"Cancers (Basel)"},{"key":"254_CR11","doi-asserted-by":"publisher","first-page":"e240223","DOI":"10.1530\/EC-24-0223","volume":"13","author":"N Patel","year":"2024","unstructured":"Patel N, Hirwa K, Gardner G, Pearce K, Jeffery J, Iqbal F, Flanagan D. Immune checkpoint inhibitor induced hypophysitis: a specific disease of corticotrophs? Endocr Connections. 2024;13:e240223.","journal-title":"Endocr Connections"},{"key":"254_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.autrev.2014.01.007","volume":"13","author":"P Caturegli","year":"2014","unstructured":"Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391\u20137.","journal-title":"Autoimmun Rev"},{"key":"254_CR13","first-page":"e34696","volume":"15","author":"S Alqaisi","year":"2023","unstructured":"Alqaisi S, Rahman A. A rare case of Pembrolizumab-Associated graves\u2019 disease. Cureus. 2023;15:e34696.","journal-title":"Cureus"},{"key":"254_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","volume":"12","author":"R Tozzoli","year":"2012","unstructured":"Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with graves\u2019 disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmune Reviews. 2012;12:107\u201313.","journal-title":"Autoimmune Reviews"},{"key":"254_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee C, Laurberg P, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421.","journal-title":"Thyroid"},{"key":"254_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s12020-023-03658-3","volume":"84","author":"A Berlinska","year":"2024","unstructured":"Berlinska A, Swiatkowska-Stodulska R. Clinical use of thyroglobulin: not only thyroid cancer. Endocrine. 2024;84:786\u201399.","journal-title":"Endocrine"},{"key":"254_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2214\/AJR.09.2459","volume":"195","author":"L Anderson","year":"2010","unstructured":"Anderson L, Middleton WD, Teefey SA, Reading CC, Langer JE, Desser T, et al. Hashimoto thyroiditis: part 1, sonographic analysis of the nodular form of Hashimoto thyroiditis. Am J Roentgenol. 2010;195:208\u201315.","journal-title":"Am J Roentgenol"},{"key":"254_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0140-6736(78)92943-4","volume":"2","author":"N Amino","year":"1978","unstructured":"Amino N, Yabu Y, Miyai K, Fujie T, Azukizawa M, Onishi T, Kumahara Y. Differentiation of thyrotoxicosis induced by thyroid destruction from graves\u2019 disease. Lancet. 1978;2:344\u20136.","journal-title":"Lancet"},{"key":"254_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1530\/EJE-13-0533","volume":"169","author":"A Carl\u00e9","year":"2013","unstructured":"Carl\u00e9 A, Knudsen N, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, Laurberg P. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. Eur J Endocrinol. 2013;169:537\u201345.","journal-title":"Eur J Endocrinol"},{"key":"254_CR20","first-page":"80","volume":"32","author":"S Jaroudi","year":"2018","unstructured":"Jaroudi S, Gavin M, Boylan K, Peiris AN. Transient T3 toxicosis associated with hashimoto\u2019s disease. Proc (Bayl Univ Med Cent). 2018;32:80\u20131.","journal-title":"Proc (Bayl Univ Med Cent)"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00254-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:03:01Z","timestamp":1752530581000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00254-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00254-7","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patient provided written informed consent for publication of the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed patient consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"35"}}